| 1 |
Tredup C, Ndreshkjana B, Schneider NS, Tjaden A, Kemas AM, Youhanna S, Lauschke VM, Berger BT, Krämer A, Berger LM, Röhm S, Knapp S, Farin HF, Müller S. Deep Annotation of Donated Chemical Probes (DCP) in Organotypic Human Liver Cultures and Patient-Derived Organoids from Tumor and Normal Colorectum. ACS Chem Biol 2023. [PMID: 36944371 DOI: 10.1021/acschembio.2c00877] [Reference Citation Analysis]
|
| 2 |
Yang X, Smith JL, Beck MT, Wilkinson JM, Michaud A, Vasta JD, Robers MB, Willson TM. Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells. bioRxiv 2023:2023. [PMID: 36865333 DOI: 10.1101/2023.02.25.529946] [Reference Citation Analysis]
|
| 3 |
Ong HW, Truong A, Kwarcinski F, de Silva C, Avalani K, Havener TM, Chirgwin M, Galal KA, Willis C, Krämer A, Liu S, Knapp S, Derbyshire ER, Zutshi R, Drewry DH. Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore. Eur J Med Chem 2023;249:115043. [PMID: 36736152 DOI: 10.1016/j.ejmech.2022.115043] [Reference Citation Analysis]
|
| 4 |
Khairnar S, Sonawane A, Cheke RS, Kharkar PS, Gaikwad V, Patil S, Aware V. Hit discovery of novel 2-phenyl-substituted 4-amino-6,7-dihydro-5H-cyclopenta[d]pyrimidines as potential anti-glioblastoma therapeutics: Design, synthesis, biological evaluation, and computational screening. Drug Dev Res 2023. [PMID: 36823756 DOI: 10.1002/ddr.22046] [Reference Citation Analysis]
|
| 5 |
Murray NH, Asquith CRM, Fang Z, East MP, Ptak N, Smith RW, Vasta JD, Zimprich CA, Corona CR, Robers MB, Johnson GL, Bingman CA, Pagliarini DJ. Small-molecule inhibition of the archetypal UbiB protein COQ8. Nat Chem Biol 2023;19:230-8. [PMID: 36302899 DOI: 10.1038/s41589-022-01168-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Outhwaite IR, Singh S, Berger BT, Knapp S, Chodera JD, Seeliger MA. Death by a Thousand Cuts â€" Combining Kinase Inhibitors for Selective Target Inhibition and Rational Polypharmacology. bioRxiv 2023:2023. [PMID: 36711619 DOI: 10.1101/2023.01.13.523972] [Reference Citation Analysis]
|
| 7 |
Ackloo S, Antolin AA, Bartolome JM, Beck H, Bullock A, Betz UAK, Böttcher J, Brown PJ, Chaturvedi M, Crisp A, Daniels D, Dreher J, Edfeldt K, Edwards AM, Egner U, Elkins J, Fischer C, Glendorf T, Goldberg S, Hartung IV, Hillisch A, Homan E, Knapp S, Köster M, Krämer O, Llaveria J, Lessel U, Lindemann S, Linderoth L, Matsui H, Michel M, Montel F, Mueller-fahrnow A, Müller S, Owen DR, Saikatendu KS, Santhakumar V, Sanderson W, Scholten C, Schapira M, Sharma S, Shireman B, Sundström M, Todd MH, Tredup C, Venable J, Willson TM, Arrowsmith CH. Target 2035 – an update on private sector contributions. RSC Med Chem 2023. [DOI: 10.1039/d2md00441k] [Reference Citation Analysis]
|
| 8 |
Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol Res 2023;187:106552. [PMID: 36403719 DOI: 10.1016/j.phrs.2022.106552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Joisa CU, Chen KA, Berginski ME, Golitz BT, Jenner MR, Herrera Loeza SG, Yeh JJ, Gomez SM. Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase Inhibitors.. [DOI: 10.1101/2022.12.06.519165] [Reference Citation Analysis]
|
| 10 |
Cartwright TN, Meyer SK, Higgins JMG. Robustness of NanoBiT luciferase complementation technology in the presence of widely used kinase inhibitors. SLAS Discov 2022;27:471-5. [PMID: 36162794 DOI: 10.1016/j.slasd.2022.09.004] [Reference Citation Analysis]
|
| 11 |
Ercoli MF, Ramos PZ, Jain R, Pilotte J, Dong OX, Thompson T, Wells CI, Elkins JM, Edwards AM, Couñago RM, Drewry DH, Ronald PC. An open source plant kinase chemogenomics set. Plant Direct 2022;6. [DOI: 10.1002/pld3.460] [Reference Citation Analysis]
|
| 12 |
Korshunova M, Huang N, Capuzzi S, Radchenko DS, Savych O, Moroz YS, Wells CI, Willson TM, Tropsha A, Isayev O. Generative and reinforcement learning approaches for the automated de novo design of bioactive compounds. Commun Chem 2022;5:129. [PMID: 36697952 DOI: 10.1038/s42004-022-00733-0] [Reference Citation Analysis]
|
| 13 |
Veríssimo GC, Serafim MSM, Kronenberger T, Ferreira RS, Honorio KM, Maltarollo VG. Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern. Expert Opin Drug Discov 2022. [PMID: 35983695 DOI: 10.1080/17460441.2022.2114451] [Reference Citation Analysis]
|
| 14 |
Yang X, Dickmander RJ, Bayati A, Taft-Benz SA, Smith JL, Wells CI, Madden EA, Brown JW, Lenarcic EM, Yount BL Jr, Chang E, Axtman AD, Baric RS, Heise MT, McPherson PS, Moorman NJ, Willson TM. Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses. ACS Chem Biol 2022. [PMID: 35723434 DOI: 10.1021/acschembio.2c00378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Tiek DM, Erdogdu B, Razaghi R, Jin L, Sadowski N, Alamillo-Ferrer C, Hogg JR, Haddad BR, Drewry DH, Wells CI, Pickett JE, Song X, Goenka A, Hu B, Goldlust SA, Zuercher WJ, Pertea M, Timp W, Cheng SY, Riggins RB. Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas. Sci Adv 2022;8:eabn3471. [PMID: 35731869 DOI: 10.1126/sciadv.abn3471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Khurana R, Schürer SC. The Clinical Kinase Index (CKI): A user friendly application to prioritize kinases as prospective cancer drug targets. Software Impacts 2022;12:100257. [DOI: 10.1016/j.simpa.2022.100257] [Reference Citation Analysis]
|
| 17 |
Veale CGL, Talukdar A, Vauzeilles B. ICBS 2021: Looking Toward the Next Decade of Chemical Biology. ACS Chem Biol 2022;17:728-43. [PMID: 35293726 DOI: 10.1021/acschembio.2c00209] [Reference Citation Analysis]
|
| 18 |
Murray NH, Lewis A, Asquith CRM, Rincon Pabon JP, Fang Z, Ptak N, Smith RW, Vasta JD, Zimprich CA, Corona CR, Robers MB, Bingman CA, Gross ML, Henzler-wildman K, Pagliarini DJ. Small Molecule Modulation of the Archetypal UbiB protein COQ8.. [DOI: 10.1101/2022.03.22.485346] [Reference Citation Analysis]
|
| 19 |
Tjaden A, Chaikuad A, Kowarz E, Marschalek R, Knapp S, Schröder M, Müller S. Image-Based Annotation of Chemogenomic Libraries for Phenotypic Screening. Molecules 2022;27:1439. [PMID: 35209227 DOI: 10.3390/molecules27041439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Maus KD, Stephenson DJ, Ali AN, Macknight HP, Huang H, Serrats J, Kim M, Diegelmann RF, Chalfant CE. Ceramide kinase regulates acute wound healing by suppressing 5-oxo-ETE biosynthesis and signaling via its receptor OXER1. Journal of Lipid Research 2022. [DOI: 10.1016/j.jlr.2022.100187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Kropiwnicki E, Binder JL, Yang JJ, Holmes J, Lachmann A, Clarke DJB, Sheils T, Kelleher KJ, Metzger VT, Bologa CG, Oprea TI, Ma'ayan A. Getting Started with the IDG KMC Datasets and Tools. Curr Protoc 2022;2:e355. [PMID: 35085427 DOI: 10.1002/cpz1.355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Yang X, Dickmander RJ, Bayati A, Taft-Benz SA, Smith JL, Wells CI, Madden EA, Brown JW, Lenarcic EM, Yount BL Jr, Chang E, Axtman AD, Baric RS, Heise MT, McPherson PS, Moorman NJ, Willson TM. Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2. bioRxiv 2022:2022. [PMID: 35018375 DOI: 10.1101/2022.01.03.474779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Lam KHB, Leon AJ, Hui W, Lee SC, Batruch I, Faust K, Klekner A, Hutóczki G, Koritzinsky M, Richer M, Djuric U, Diamandis P. Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity. Nat Commun 2022;13:116. [PMID: 35013227 DOI: 10.1038/s41467-021-27667-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 24 |
Potjewyd FM, Annor‐gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery. A&D Transl Res & Clin Interv 2022;8. [DOI: 10.1002/trc2.12246] [Reference Citation Analysis]
|
| 25 |
Potjewyd FM, Annor‐gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology. A&D Transl Res & Clin Interv 2022;8. [DOI: 10.1002/trc2.12253] [Reference Citation Analysis]
|
| 26 |
Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res 2021;175:106037. [PMID: 34921994 DOI: 10.1016/j.phrs.2021.106037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 27 |
Mashelkar KK, Byun WS, Ko H, Sung K, Tripathi SK, An S, Yum YA, Kwon JY, Kim M, Kim G, Kwon EJ, Lee HW, Noh M, Lee SK, Jeong LS. Discovery of a Novel Template, 7-Substituted 7-Deaza-4'-Thioadenosine Derivatives as Multi-Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:1290. [PMID: 34959689 DOI: 10.3390/ph14121290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Zhao Z, E. Bourne P. Using the Structural Kinome to Systematize Kinase Drug Discovery. Protein Kinases - Promising Targets for Anticancer Drug Research 2021. [DOI: 10.5772/intechopen.100109] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Russ N, Schröder M, Berger BT, Mandel S, Aydogan Y, Mauer S, Pohl C, Drewry DH, Chaikuad A, Müller S, Knapp S. Design and Development of a Chemical Probe for Pseudokinase Ca2+/calmodulin-Dependent Ser/Thr Kinase. J Med Chem 2021;64:14358-76. [PMID: 34543009 DOI: 10.1021/acs.jmedchem.1c00845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Kalogirou AS, East MP, Laitinen T, Torrice CD, Maffuid KA, Drewry DH, Koutentis PA, Johnson GL, Crona DJ, Asquith CRM. Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors. Molecules 2021;26:5911. [PMID: 34641454 DOI: 10.3390/molecules26195911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Serafim RAM, Elkins JM, Zuercher WJ, Laufer SA, Gehringer M. Chemical Probes for Understudied Kinases: Challenges and Opportunities. J Med Chem 2021. [PMID: 34477374 DOI: 10.1021/acs.jmedchem.1c00980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 32 |
Demuro S, Di Martino RMC, Ortega JA, Cavalli A. GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. Int J Mol Sci 2021;22:9098. [PMID: 34445804 DOI: 10.3390/ijms22169098] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 33 |
Škuta C, Southan C, Bartůněk P. Will the chemical probes please stand up? RSC Med Chem 2021;12:1428-41. [PMID: 34447939 DOI: 10.1039/d1md00138h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Drewry DH, Annor-Gyamfi JK, Wells CI, Pickett JE, Dederer V, Preuss F, Mathea S, Axtman AD. Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration. J Med Chem 2021. [PMID: 34333981 DOI: 10.1021/acs.jmedchem.1c00440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Potjewyd FM, Annor-gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson T, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. AD Informer Set: Chemical tools to facilitate Alzheimer’s disease drug discovery.. [DOI: 10.1101/2021.07.22.453404] [Reference Citation Analysis]
|
| 36 |
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological Research 2021;165:105463. [DOI: 10.1016/j.phrs.2021.105463] [Cited by in Crossref: 158] [Cited by in F6Publishing: 165] [Article Influence: 79.0] [Reference Citation Analysis]
|
| 37 |
Tiek DM, Erdogdu B, Razaghi R, Jin L, Sadowski N, Alamillo-ferrer C, Hogg JR, Haddad BR, Drewry DH, Wells CI, Pickett JE, Song X, Goenka A, Hu B, Goldlust SL, Zuercher WJ, Pertea M, Timp W, Cheng S, Riggins RB. Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas.. [DOI: 10.1101/661660] [Reference Citation Analysis]
|
